Incidence and Risk Factors for Weight Loss During Dual HIV/Hepatitis C Virus Therapy
| Autor: | Brian L. Strom, Donald D. Stieritz, Babette S. Zemel, Robert E. Gross, Mary E. Putt, Hanna Rennert, Ian Frank, K. Rajender Reddy, Vincent Lo Re, Karam Mounzer, Jay R. Kostman |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents Hepatitis C virus HIV Infections Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Polyethylene Glycols Cohort Studies chemistry.chemical_compound Risk Factors Weight loss Antiretroviral Therapy Highly Active Internal medicine Ribavirin Weight Loss medicine Humans Pharmacology (medical) Risk factor Prospective cohort study Retrospective Studies business.industry Incidence (epidemiology) Hazard ratio Interferon-alpha virus diseases Retrospective cohort study Middle Aged Hepatitis C Recombinant Proteins digestive system diseases Infectious Diseases chemistry Immunology Female medicine.symptom business |
| Zdroj: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 44:344-350 |
| ISSN: | 1525-4135 |
| DOI: | 10.1097/qai.0b013e31802f12d3 |
| Popis: | BACKGROUND Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically. OBJECTIVES To determine if the incidence and degree of weight loss among patients with HIV/HCV receiving highly active antiretroviral therapy (HAART) and pegylated (PEG)-interferon plus ribavirin were greater than in (1) HCV-monoinfected patients receiving PEG-interferon plus ribavirin and (2) HIV-monoinfected patients receiving HAART. Risk factors for weight loss among patients with HIV/HCV were also examined. METHODS A retrospective cohort study was performed among HIV/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected patients. Body weights were assessed up to 6 months before and up to 12 months after initiation of HCV therapy (HIV/HCV-coinfected and HCV-monoinfected subjects) and over 18 months on HAART (HIV-monoinfected subjects). The primary outcome was clinically significant weight loss (> or =5% of baseline weight). RESULTS Of 192 subjects, 63 had HIV/HCV, 64 had HCV alone, and 65 had HIV alone. Clinically significant weight loss occurred in 48 (76%) subjects with HIV/HCV versus 25 (39%) subjects with HCV (P < 0.001) and 2 (3%) subjects with HIV (P < 0.001), yielding adjusted hazard ratios (HRs) of 2.76 (95% confidence interval [CI]: 1.67 to 4.55) and 38.5 (95% CI: 8.5 to 174.7), respectively. Receipt of more than 2 nucleoside reverse transcriptase inhibitors increased the risk of clinically significant weight loss (adjusted HR = 8.17, 95% CI: 2.37 to 28.20). CONCLUSIONS The incidence of weight loss is greater in dually treated patients with HIV/HCV than in treated HCV- or HIV-monoinfected patients. Prospective studies should evaluate additional risk factors for weight loss and changes in body composition to elucidate the mechanism for this weight loss. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|